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Abstract: Krüppel-like factor (KLF) family members share a three C2H2 zinc finger DNA binding domain, and are in-
volved in cell proliferation and differentiation control in normal as in pathological situations. Studies over the past several 
years support a significant role for this family of transcription factors in carcinogenesis. KLFs can both activate and re-
press genes that participate in cell-cycle regulation. Among them, many up-regulated genes are inhibitors of proliferation, 
whereas genes that promote cell proliferation are repressed. However, several studies do present KLFs as positive regula-
tor of cell proliferation. KLFs can be deregulated in multiple cancers either by loss of heterozygosity (LOH), somatic mu-
tation or transcriptional silencing by promoter hypermethylation. Accordingly, KLF expression was shown to mediate 
growth inhibition when ectopically expressed in multiple cancer-derived cell lines through the inhibition of a number of 
key oncogenic signaling pathways, and to revert the tumorogenic phenotype in vivo. Taken together, these observations 
suggest that KLFs act as tumor suppressor. However, in some occasion, KLFs could act as tumor promoters, depending 
on “cellular context”. Thus, this review will discuss the roles and the functions of KLF family members in carcinogenesis, 
with a special focus on cancers from epithelial origin. 
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1. EXPRESSION AND FUNCTION OF KLF IN GAS-
TROINTESTINAL TRACT TUMORS 
A. Expression and Function of KLF in Intestinal and   
Colon Tumors 
  KLF4 or gut-enriched KLF (GKLF) is expressed exten-
sively in the gastrointestinal (GI) tract from where it was 
first identified to maintain enterocyte differentiation and 
restrain cell proliferation. In mice, KLF4 level peaks by em-
bryonic day 17 [1]. In the newborn, KLF4 level is higher in 
colon than in small intestine although the levels in both or-
gans rise with increasing age [1]. In human, KLF4 protein is 
prominent at the epithelium surface in normal colon, and its 
expression gradually decreases toward the crypt [2, 3]. In 
RKO cells (human colon cancer-derived cells), KLF4 stimu-
lates intestinal alkaline phosphatase (IAP) gene expression, 
through a critical region including the IF-III cis element lo-
cated within the proximal IAP promoter region [4]. In HCT-
116 cells (human colon cancer-derived cells), KLF4 in-
creases urokinase-type plasminogen activator receptor (u-
PAR) [5]. Inversely, level of KLF4 transcript is significantly 
decreased in intestine during tumor formation in Min mice, a 
model of intestinal tumorogenesis, suggesting that KLF4 
may play a role in gut development and/or tumor burden [1, 
6]. KLF4 mRNA and protein levels are significantly and 
gradually decreased in the dysplasic epithelium of colon, as 
in adenomatous polyp and colorectal cancer (CRC) [2, 3, 7].  
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In familial adenomatous polyposis (FAP) patients, KLF4 
transcript level is lower in adenomas compared to paired 
normal-appearing mucosa [6].  
  The molecular mechanisms involved in KLF4 loss of 
expression are still unclear. The gene encoding KLF4 is lo-
calized on chromosome 9q, previously shown to exhibit loss 
of heterozigosity (LOH) in CRC [8]. LOH in KLF4 is found 
in 83% of CRC-derived cell lines, and in 20% of CRC [8]. 
Using methylation-specific PCR, Dang DT et al. showed that 
KLF4 DNA is not methylated in either normal or tumor tis-
sues from adenomas of Min mice [6]. However, KLF4 ex-
pression is stimulated by treating CRC-derived cell lines 
with 5-Aza-2-deoxycytidine (5-Aza-dC), implicating under-
lying aberrant epigenetic modifications [3]. Again, KLF4 is 
methylated in a subset of tumors and cell lines [8]. Other 
chemicals are used to modulate KLF expression: 5,5’-
DibromoDIM up-regulates expression of KLF4 in CRC-
derived cell lines, and may represent a novel class of mecha-
nism-based therapeutic drug for CRC [9]. Several point mu-
tations in KLF4 result in a diminished ability to transactivate 
antiproliferative genes [8]. In addition, KLF4 expression is 
stimulated following treatment of HT-29 colon cancer cells 
with IFN-  and Stat-1 recruitment [10]. In FAP, KLF4 is 
induced upon activation of the adenomatous polyposis coli 
(APC) gene [11-13], probably via CDX2 [11]. KLF4 protein 
is predominantly expressed in cytoplasm but not in nucleus 
of CRC-derived cells, suggesting that impaired nuclear trans-
location of KLF4 contributes to cancer formation [14]. Last, 
KLF4 expression is inversely correlated to beta-catenin/Tcf 
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  KLF4 is required for the terminal differentiation of gob-
let cells in the mouse intestine. Notch signaling pathway 
suppresses goblet cell formation and is up-regulated in intes-
tinal tumors. Interestingly, KLF4 promoter activity is inhib-
ited by Notch, which controls goblet cell differentiation in 
mouse GI tract [16], when Notch signaling suppresses KLF4 
expression to support intestinal tumors and CRC progression 
[17]. 
  KLF4 expression is extensively lost in CRC and a down-
stream target of tumor suppressor genes, suggesting that its 
re-expression may counteract CRC progression. In cultured 
cells, expression of KLF4 is associated with growth arrest 
[18]. Constitutive expression of KLF4 in human CRC-
derived cells decreases colony formation, cell proliferation, 
cell migration, invasion, and in vivo tumorogenesis [19]. As 
a regulator of gene expression, KLF4 acts trough multiple 
pathways: (i) induction of p21
WAF1/CIP1 to maintain the integ-
rity of both G1/S [20] and G2/M [21] cell cycle checkpoints 
following DNA damage, reduction of cyclin D1 activity by 
interaction with the Sp1 binding domain on its promoter 
[22], (ii) repression of beta-catenin expression [12], and (iii) 
inhibition of ornithine decarboxylase promoter activity 
through a target, GC-rich, region [23]. Of importance, KLF4 
exerts a global inhibitory effect on protein and cholesterol 
biosynthesis [24]. Interestingly, recent studies suggest that 
KLF4 functions as an activator or repressor of transcription 
depending on whether it interacts with co-activators such as 
p300 and CREB-binding protein or co-repressors such as 
histone deacetylase HDAC3 [25]. Taken together, these 
studies clearly demonstrate that KLF4 plays an essential role 
in the regulation of cell growth in the colon.  
  Additional KLF family members modulate colon-derived 
cells proliferation. Despite binding to similar, if not identi-
cal, cis-acting DNA sequences, KLF4 and KLF5 often ex-
hibit opposite effects on regulation of gene transcription and 
cell proliferation [26]. KLF5 promotes proliferation of intes-
tinal epithelia in response to lysophophatidic acid (LPA) 
[27]. KLF5 protein expression correlates with activating 
KRAS mutations in intestinal tumors in vitro and in  vivo 
[28]. Also, KLF5 modulates p53-independent apoptosis 
through Pim1 survival kinase [29]. Targeting KLF5 results 
in cell proliferation, transformation and multi-cellular tumor 
spheroids (MCTS) inhibition [28, 30]. Also, decreasing 
KLF5 expression using all-trans retinoic acid inhibits prolif-
eration of intestinal epithelial cells [31]. As a consequence, 
small-molecule compounds are screened on their ability to 
inhibit the activity of this KLF family member [32]. How-
ever, KLF5 becomes anti-proliferative upon TGF-mediated 
acetylation, to maintain epithelial homeostasis [33].  
  It is less clear how KLF6 expression is regulated in CRC 
samples. Several studies describe the frequent inactivation 
by mutation of this putative tumor-suppressor gene [34, 35]. 
KLF6 mutants lose the ability to induce p21WAF1/CIP1, and fail 
to inhibit CRC-derived cells growth [34]. LOH of KLF6 
locus at chromosome 10p15 contributes to the development 
of non-polypoid colorectal carcinoma [36], and in the inva-
sion step from an intra-mucosal to an invasive carcinoma 
[37]. On the other hand, these findings are challenged by the 
absence of somatic mutations in DNA extracted from frozen 
tissue samples from larger series of CRC [38]. Interestingly, 
IGF-1, a well-known proliferation promoter, induces KLF6 
expression in a p53-dependent manner [39]. Last, a recent 
study demonstrates that KLF9 expression is deregulated in 
CRC, suggesting that this KLF family member may also be 
involved in the carcinogenesis of human colorectal cancer 
[40]. 
B. Expression and Function of KLF in Gastric, Esophag-
eal and Bladder Cancers 
  In addition to colon, KLFs exert opposite effects on cell 
proliferation in numerous examples; while KLF4 and KLF6 
inhibit cell growth, KLF5 stimulates proliferation. In gastric 
cancer, loss of KLF4 expression in primary tumors is associ-
ated with poor survival [41, 42]. In parallel, KLF4 mutant 
mice show increased proliferation and altered differentiation 
of their gastric epithelia [42]. Interestingly, KLF5 expression 
is also reduced in gastric carcinomas [43]. Disrupted KLF4 
expression contributes to Sp1 over-expression, and to the 
development and progression of human gastric cancer [44]. 
Mechanistic studies indicate that promoter hypermethylation 
and hemizygous deletion contribute to KLF4 down-
regulation in cancer [41]. However, epigenetic alterations of 
KLF4 in gastric oncogenesis is still debated [45]. Enforced 
expression of KLF4 results in cell proliferation and tumor 
growth inhibition [41]. In addition, somatic missense muta-
tions are identified in the activation domain of the KLF6 
gene in gastric carcinoma [46]. KLF6 LOH is observed in 16 
of 37 informative cases [46]. These data suggest that genetic 
alterations of KLF6 gene play an important role in the devel-
opment or the progression of sporadic gastric cancers [46]. 
KLF6 mutants are demonstrated to increase tumorigenicity 
in vivo [47]. However, a recent study demonstrates that the 
IVS1 -27G/A polymorphism of KLF6 is not associated with 
an increased risk of gastric cancer in Korean population [48]. 
  Down-regulation of KLF4 expression is also reported in 
esophageal cancer [49], while over-expression of KLF5 in 
esophageal epithelia leads to an increase of proliferation in 
basal cells, in vivo [50]. KLF4 represses the transcription of 
survivin in esophageal squamous cancer cells, which is in 
favor of an antiproliferative effect [51]. Last, KLF5 tran-
scription factor is described to play an oncogenic role in a 
human bladder cancer cell line, via increased G1 to S phase 
transition, up-regulation of cyclin D1 expression, phosphory-
lation of MAPK and Akt proteins, and inhibition of p27 and 
p15 expression [52]. 
C. Expression and Function of KLF in Hepatocellular 
Carcinoma 
  KLF6 expression and function have been extensively 
investigated in hepatocellular carcinoma (HCC). KLF6 was 
first shown to be frequently inactivated either by LOH 
and/or inactivating somatic mutations, and that its inactiva-
tion contributes to pathogenesis of HCC [53-57]. Whereas 
wild-type KLF6 decreases cellular proliferation of HCC-
derived cells, patient-derived KLF6 mutants do not [54, 55]. 
Also, these mutants are unable to transactivate p21WAF1/CIP1 
promoter [55]. DNA methylation may marginally participate 
to KLF6 down-regulation in HCC [56, 58]. However, de-
regulation of KLF6 stability following ubiquitination may 
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lines [59]. Transgenic expression of KLF6 in the liver results 
in decreased body and liver size, with decreased hepatocyte 
proliferation, when KLF6 +/- mice display increased liver 
mass with reduced p21 expression [60]. 
  However, KLF6 status in HCC is still largely debated. 
No somatic mutations are found in freshly isolated HCC 
samples [57, 61, 62], and no difference in KLF6 expression 
are detected between HCC and adjacent normal liver [57]. 
However, KLF6 expression is inhibited in macronodules, as 
compared to cirrhosis and HCC [62]. Finally, KLF6 is essen-
tial for HCC-derived cells to evade apoptosis [63, 64]. To-
gether with the results describing KLF6 as a tumor suppres-
sor gene, the latter observations create a paradox and indi-
cate that not only loss, but also enforced expression of KLF6 
contribute to tumorigenesis. This phenomenon is still not 
totally understood, and can be attributed to 'cell-type' speci-
ficity. Further studies are needed to identify such cellular 
factors, for KLF6 to switch from a growth-inhibiting tumor 
suppressor to a growth-promoting oncogene. In fact, KLF6 
alternative splicing that yield a dominant negative, prolifera-
tion-prone, KLF6-SV1 isoform is described in HCC [65] and 
in nonalcoholic fatty liver disease [66]. KLF6 alternative 
splicing in HCC is promoted by oncogenic KRAS [65]. Thus, 
the discrepancy considering KLF6 expression and function 
in HCC may reside in the identification of the molecular 
isoform of this transcription factor. 
2. EXPRESSION AND FUNCTION OF KLF IN OTHER 
EPITHELIAL CANCERS 
A. Expression and Function of KLF in Prostate Cancer 
  KLF6 expression is altered in prostate cancer [67]. LOH 
analysis reveals that KLF6 allele is deleted in 77% of pri-
mary prostate tumors [67]. Again, tumor-derived KLF6 mu-
tants fail to transactivate p21
WAF1/CIP1, and to impede cell 
proliferation [67, 68], when wild type KLF6 induces apoto-
sis in prostate cancer cells via the ATF3 transcription factor 
[69]. A germline KLF6 single nucleotide polymorphism 
(IVS1-27G>A), together with increased transcription of 
three alternatively spliced KLF6 isoforms is reported in pros-
tate cancer. KLF6 protein variants KLF6 SV1 and KLF6 
SV2 are mislocalized to the cytoplasm, antagonize wtKLF6 
function, leading to a decreased p21 expression and to an 
increased cell growth. These variants are up-regulated in 
tumor versus normal prostatic tissue [70]. KLF6 SV1 is 
demonstrated to be essential for prostate cancer cell growth 
and spread [71]. However, significant genetic alterations of 
KLF6 seem restricted to a minority of high-grade prostate 
cancers [72]. Again, the finding of a broad loss of KLF6 
expression in prostate cancer is strongly challenged by inde-
pendent studies reporting the infrequent germ-line mutation 
of KLF6, or the presence of KLF6 IVS1-27G>A polymor-
phism, in prostate cancer [73-77]. Last, this polymorphism 
predicts the metastatic behavior of the tumors [78]. Taken 
together, KLF6 SV1 is a novel therapeutic target for prostate 
cancer. Selenium supplementation is effective in reducing 
the incidence of prostate cancer. Interestingly, selenium in-
duces KLF4 expression in two cancer cell lines, derived 
from either androgen-dependent or androgen-independent 
prostate cancer [79]. Over-expression of KLF4 not only 
leads to an induction of apoptosis in control cells, but also 
enhances the DNA-suppressive and pro-apoptotic activities 
of selenium [79]. Thus, KLF4 may also play a key role in 
prostate cancer control. 
B. Expression and Function of KLF in Breast and Ovar-
ian Cancers 
  KLF4 expression is associated with breast cancer pro-
gression. Increased KLF4 expression is observed in neopla-
sic cells compared to adjacent uninvolved epithelium [80]. 
KLF4 is activated prior to invasion through the basal mem-
brane [80]. Its nuclear localization is associated with an ag-
gressive phenotype in early-stage breast cancer [81]. On the 
other hand, KLF5 is a potential tumor suppressor gene in 
breast cancer [82]. KLF5 undergoes haplo-insufficiency dur-
ing breast carcinogenesis, without evidence of neither point 
mutation, nor promoter methylation nor homozygous dele-
tion [82]. Re-expression of KLF5 in breast cancer-derived 
cells inhibits colony formation [82]. Unfortunately, a recent 
study demonstrates that patients with a higher KLF5 expres-
sion have a shorter disease-free survival and overall survival 
than those observed in patients with a lower KLF5 expres-
sion [83]. Thus, KLF5 expression and/or function in breast 
cancer remain to be elucidated. 
  Other KLF family members are involved in breast cancer 
progression. Tissue factor pathway inhibitor-2 (TFPI-2) is a 
matrix-associated Kunitz inhibitor that inhibits plasmin and 
trypsin-mediated activation of zymogen matrix metalloprote-
inases involved in tumor progression, invasion and metasta-
sis. Its expression is lost in highly invasive breast cancer 
caused by DNA hypermethylation, and as a consequence, a 
lack in KLF6 transactivation [84]. Interestingly, KLF6 re-
duction in an ovarian cancer-derived cell line results in a 
reduction of E-cadherin expression. Conversely, KLF6-SV1 
silencing strongly up-regulates E-cadherin, which alters 
ovarian tumor invasion and metastasis [85, 86]. KLF8 plays 
a critical role in oncogenic transformation and in epithelial to 
mesenchymal transition [87]. KLF8 negatively regulates E-
cadherin expression which promotes human breast cancer 
invasion and metastasis [88]. In ovarian cancer cells, KLF8 
expression is induced by FAK, by activating the PI3K-Akt 
signaling pathway [89]. 
C. Expression and Function of KLF in Pancreatic Cancer 
  KLF4 is up-regulated in pancreatic intraepithelial neopla-
sia, a known precursor lesion of pancreatic cancer [90]. Ec-
topic expression of KLF4 results in cell cycle arrest of pan-
creatic carcinoma-derived BxPC-3 cells. In addition, cell 
growth is inhibited, as tumor growth and metastasis in an 
orthotopic mouse model. This anti-proliferative effect is due 
to the interaction of KLF4 with p27(Kip1) promoter [91]. 
KLF6 is neither lost nor mutated in pancreatic cancer, but 
accumulates in cytoplasm of the cancer cells caused by an 
alternative splicing [92]. Interestingly, KLF6 splicing corre-
lates with tumor stage and survival, and may be useful as a 
prognostic factor. 
D. Expression and Function of KLFs in Lung Carcinoma 
  Lung KLF (LKLF) is identified as a transactivator of 
cytosolic phospholipase A2 (cPLA2) in lung epithelial and 
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expression of a dominant negative form of LKLF inhibits the 
induction of cPLA2 promoter activity by RAS [93]. Because 
cPLA2 is critical for increased eicosanoid production associ-
ated with lung tumorogenesis, targeting LKLF may be of 
interest to treat NSLC. In addition, NSLC exhibit frequent 
allelic loss at chromosome 10p15 where KLF6 is located. 
Although somatic mutations are not detected in the coding 
sequence of KLF6, expression of KLF6 mRNA is down-
regulated in 85% of primary tumors [94]. Thirty-four percent 
of informative samples had LOH in the KLF6 gene locus, 
without evidence of promoter hypermethylation [94]. En-
forced expression of KLF6 resulted in NSLC-derived cells 
apoptosis [94], while PKC activates KLF6 to mediate lung 
cancer-derived cell lines growth inhibition [95]. In addition, 
a potential involvement of KLF6 IVS1-27G>A polymor-
phism is associated with lung cancer risk [96]. Again, an 
increased expression of KLF6 SV1 is observed in lung ade-
nocarcinoma, and is associated with a decreased survival in 
patients. In lung cancer cell lines, KLF6 SV1 protects cells 
from apoptosis, and its targeted reduction induces apoptosis 
[94, 97, 98]. 
E. Expression and Function of KLF in Skin Cancers 
  In melanoma cell lines, KLF4 expression is down-
regulated as a result of homozygous deletion of the 
CDKN2A locus [99]. A similar study identifies an up-
regulation of KLF5 in three melanoma cell lines with the 
most common and potent V600E mutation in B-RAF gene 
[100]. Several studies illustrate the function of KLF family 
members in skin squamous cell carcinoma (SCC). When 
induced in basal keratinocytes in vitro, KLF4 abolishes the 
distinctive properties of basal and parabasal epithelial cells 
[101]. Nuclear KLF4 causes a transitory apoptotic response 
and the skin progresses through phases of hyperplasia and 
dysplasia [101]. By 6 weeks, lesions highly resemble SCC 
[101]. KLF4 expression is later demonstrated to be associ-
ated with human skin SCC progression, as constitutive nu-
clear KLF4 staining pattern is detected in moderately and 
poorly differentiated tumors and metastasis [102, 103]. In-
terestingly, retinoid receptors including RXR can be used 
to prevent KLF4-mediated transformation and tumorogene-
sis, in vitro and in vivo [104]. 
3. EXPRESSION AND FUNCTION OF KLFS IN MIS-
CELLANEOUS CANCERS 
A. Expression and Function of KLFs in Central Nervous 
System Tumors 
  Dysfunction of KLF family members can contribute to 
oncogenesis in the brain. Gliomas are frequent tumors of the 
central nervous system with a poor prognosis. Because dele-
tion of chromosome 10p15 is one of the most common 
chromosomal alterations in gliomas, KLF6 LOH is detected 
in 90% of glioblastoma samples [105], without evidences of 
KLF6 somatic mutations [105-108]. Mutations in KLF6 se-
quence are absent in astrocytic tumors [109], in meningio-
mas [106], and in sporadic pituitary tumors [110]. In addi-
tion, mutations of KLF6 are infrequent (5.5% to 11.8%) in 
anaplastic astrocytomas, in low-grade diffuse astrocytomas 
and in oligodendrogliomas [108]. Still, KLF6 expression is 
attenuated in human glioblastomas, when compared to pri-
mary astrocytes [105, 111, 112]. KLF6 mutants loose their 
ability to reduce growth rate of glioma cells [111, 112], 
whereas KLF6 SV1 expression is increased in glioblastomas 
to sustain cell proliferation [105]. 
B. Expression and Function of KLFs in Hematological 
Malignancies 
  KLF4, KLF9 and promyelocytic leukemia zinc finger 
(PLZF) are involved in maintaining cellular quiescence of 
naive B cells [113]. However, the accelerated response of 
memory B cells after activation through CD40 and the B cell 
receptor correlates with reduced expression of these genes, 
and the subsequent regulatory effects they exert on the cell 
cycle [113]. In accordance, KLF4 is a putative tumor sup-
pressor in B-cell malignancies [114], whereas KLF5 confers 
drug resistance to acute lymphoblastic leukemia by promot-
ing survivin expression [115]. Yasunaga et al. identified 
aberrantly hypermethylated DNA sequences, including 
KLF4 gene, in adult T-cell leukemia (ATL) [116]. Restoring 
KLF4 expression in ATL-derived cell lines induces cell 
death by apoptosis [116]. PLZF implication in hematological 
malignancies is more complex. PLZF is involved in the pro-
duction of chimeric proteins formed by chromosomal trans-
locations with retinoic acid receptor alpha to produce a 
dominant negative transcription factor that can decrease the 
expression of tumor suppressor genes [117]. In acute pro-
myelocytic leukemia, RAR-PLZF overcomes PLZF to con-
tribute to retinoic resistance [118]. In addition, increased 
expression of PLZF is a predictor of long-term survival in 
malignant melanoma patients [119]. The silencing of PLZF 
in melanoma-derived cells unblocks miR-221/-222 expres-
sion which in turn leads to enhanced proliferation [120]. In-
terestingly, CDK2 phosphorylates PLZF, which impairs 
PLZF transcriptional repression ability and antagonizes its 
growth inhibitory effects [121].  
CONCLUSION 
  KLF family member proteins play a critical role in the 
growth and metastasis of numerous tumor types, at least in 
part by regulating the expression of cell cycle genes. Glob-
ally, KLF4 and KLF6 are considered as tumor suppressor 
gene, whereas KLF5 promotes cell proliferation. Family 
members have different transcriptional properties and can 
modulate each other's activity by a variety of mechanisms. 
Since cells can express multiple KLFs, KLF transcription 
factors build likely a transcriptional network to control cell 
proliferation. Effects of changes in KLF factors are context-
dependent and can appear contradictory, considering differ-
ences in the expression profile of family members in various 
cells. Last, KLF variants may antagonize the function of 
wild type proteins. 
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